Inhibition of Cyclic GMP Export by Multidrug Resistance Protein 4: A New Strategy to Treat Erectile Dysfunction?
- 28 February 2017
- journal article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 14 (4) , 502-509
Abstract
Background: Intracellular cyclic guanosine monophosphate (cGMP) concentrations are regulated by degradation enzymes (phosphodiesterases) and by active transport across the plasma membrane by multidrug resistance proteins (MRPs) 4 and 5.Aim: To evaluate the functional effect of MRP-4 inhibition and the role of MRP-4–mediated cGMP export in mouse corpora cavernosa.Methods: Isometric tension of mouse corpora cavernosa was measured after cumulative addition of MK-571, an inhibitor of MRP-4, or sildenafil, a phosphodiesterase type 5 inhibitor. In addition, the effect of MRP-4 inhibition on cGMP-independent and cGMP-dependent relaxations was studied. In vivo intracavernosal pressure and mean arterial pressure measurements were performed after intracavernosal injection of MK-571. The effect of MRP-4 inhibition on cGMP content was determined using an enzyme immunoassay kit.Outcomes: Measurement of the effect of MK-571 on cGMP content, relaxant responses of mouse corpora cavernosa to cGMP-independent and cGMP-dependent vasodilating substances, and determination of the ratio of intracavernosal pressure to mean arterial pressure after intracavernosal injection of MK-571.Results: MK-571 and sildenafil relaxed the corpora cavernosa concentration dependently, with sildenafil being the more potent relaxing compound. Furthermore, MK-571 enhanced relaxing responses to cGMP-dependent substances, such as sodium nitroprusside, sildenafil, acetylcholine, and electrical field stimulation, with the latter even under in vitro diabetic conditions. In contrast, cGMP-independent relaxations were not altered by MRP-4 inhibition. Intracavernosal administration of MK-571 significantly increased intracavernosal pressure, with minimal effect on mean arterial pressure. The cGMP analysis showed that MRP-4 inhibition was accompanied by increased cGMP levels.Clinical Translation: MRP-4, at least when targeted locally in the penis or when combined with a phosphodiesterase type 5 inhibitor, might be a valuable alternative strategy for the treatment of (diabetic) erectile dysfunction.Strengths and Limitations: This study is the first to demonstrate an in vitro direct relaxant and an in vivo pro-erectile effect of the MRP-4 inhibitor, MK-571, on mouse corpora cavernosa. However, the functional effect of MRP-5–mediated export in mouse corpora cavernosa was not explored, which has been suggested to play the predominant role in cGMP export.Conclusion: Inhibition of MRP-4 increases basal and stimulated levels of cGMP, leading to corpora cavernosa relaxation and penile erection. Therefore, in addition to degradation of cGMP, export of cGMP by MRP-4 could contribute substantially to regulating cGMP levels in mouse corpora cavernosa.Keywords
Funding Information
- Special Investigation Fund of Ghent University (01G02410)
This publication has 20 references indexed in Scilit:
- Lack of effect of ODQ does not exclude cGMP signalling via NO‐sensitive guanylyl cyclaseBritish Journal of Pharmacology, 2013
- Inhibition of MRP4 prevents and reverses pulmonary hypertension in miceJournal of Clinical Investigation, 2011
- Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferationJournal of Clinical Investigation, 2008
- Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling moleculesTrends in Pharmacological Sciences, 2008
- Oxidative and electrophilic stress induces multidrug resistance–associated protein transporters via the nuclear factor-E2–related factor-2 transcriptional pathwayHepatology, 2007
- Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosumEuropean Journal of Pharmacology, 2006
- Endothelial dysfunction in diabetic erectile dysfunctionInternational Journal Of Impotence Research, 2006
- Cyclic GMP transportersNeurochemistry International, 2004
- Expression and Localization of the Multidrug Resistance Protein 5 (MRP5/ABCC5), a Cellular Export Pump for Cyclic Nucleotides, in Human HeartThe American Journal of Pathology, 2003
- The Multidrug Resistance Protein 5 Functions as an ATP-dependent Export Pump for Cyclic NucleotidesJournal of Biological Chemistry, 2000